There are 2789 resources available
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display
543P - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Presenter: Mark Lythgoe
Session: ePoster Display
613P - Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niamh Keegan
Session: ePoster Display
505TiP - REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
Presenter: Giacomo Bregni
Session: ePoster Display
506TiP - Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study
Presenter: Takayuki Yoshino
Session: ePoster Display
675P - Changes in treatment patterns and survival in renal cell carcinoma (RCC) patients in Norway: A nationwide registry study for 1995-2018
Presenter: Katarina Puco
Session: ePoster Display
617P - Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project
Presenter: Taigo Kato
Session: ePoster Display